Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Campath-1H alemtuzumab: Phase III data; marketed to treat B-CLL

In a German Phase III trial, 6 patients given Campath following front-line fludarabine-based therapy

Read the full 144 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE